Michael Nicolosi, DO
Physical Medicine and Rehabilitation · Freeport, NYNPI 1093944647
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,023 of the $8,829 with a category attached, or 68.2%. 20 manufacturers reported payments, led by Medtronic at 30.2% of the total. Reporting peaked in 2024 at $3,364 and has fallen 58.5% since, to $1,397 in 2025. Among physical medicine and rehabilitation clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $54.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$3K
- Abbott$2K
- AbbVie$348
- Relievant Medsystems, Inc.$266
- Nevro Corp.$263
- plus $1K from 14 others
What the payments were for
- Travel & lodging$2,80732%
- Food & beverage$6,02368%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 46 | $2,664 |
| Boston Scientific | 41 | $2,575 |
| Abbott | 15 | $1,650 |
| AbbVie(2 entities) | 18 | $348 |
| Relievant Medsystems, Inc. | 8 | $266 |
| Nevro Corp. | 7 | $263 |
| Johnson & Johnson | 2 | $250 |
| Amarin Pharma, Inc. | 2 | $250 |
| Sanofi-aventis U.S. LLC | 1 | $114 |
| Pfizer | 5 | $97 |
| Valinor Pharma, LLC | 3 | $63 |
| Redhill Biopharma Inc. | 3 | $59 |
| Globus Medical | 3 | $56 |
| Collegium Pharmaceutical, Inc. | 2 | $40 |
| Orexo US, Inc. | 2 | $40 |
| Vertex | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $17 |
| Forte Bio-pharma LLC | 1 | $17 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$1,426
- Proclaim Family of SCS IPGs$1,423
- INTELLIS ADAPTIVESTIM$1,395
- WATCHMAN FLX$271
- XARELTO$250
- Vascepa$250
- INCEPTIV$166
- INTELLIS$142
- VANTA ADAPTIVESTIM$123
- DISEASE STATE$114
- Senza$101
How this compares
$8,829 in reported general payments places this provider in the 95th percentile of 872 physical medicine and rehabilitation providers in New York.
See all physical medicine and rehabilitation providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SublocadeBuprenorphine | 18 | $36,350 |
| MovantikNaloxegol Oxalate | 44 | $18,841 |
| LinzessLinaclotide | 22 | $11,089 |
| Lidocaine | 113 | $10,458 |
| Diclofenac Sodium | 67 | $8,513 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 75 | $7,964 |
| Oxycodone Hcl | 284 | $6,385 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 283 | $6,199 |
| ZtlidoLidocaine | 16 | $5,890 |
| Morphine Sulfate ErMorphine Sulfate | 90 | $3,674 |
| Gabapentin | 209 | $2,068 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 85 | $2,011 |
| Tizanidine Hcl | 118 | $1,042 |
| Cyclobenzaprine Hcl | 116 | $808 |
| Pregabalin | 70 | $770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $59 | $18,84144 claims |
| AbbVieLinzess | $348 | $11,08922 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $21 | $5,89016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 872 physical medicine and rehabilitation providers in New York.
Other physical medicine and rehabilitation in Freeport
- Heidi FuscoNew York$153K
- Geraldine DapulRochester$77K
- Michael OdellNew York$67K
- Craig AntellNew York$65K
- Michael StubblefieldNew York$53K
- Heakyung KimNew York$53K
- Jeffrey BazarianRochester$47K
- Martin SchaefferLiverpool$41K
- Michael CicchettiWilliamsville$36K
- Russell SilverNew York$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.